Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Receives $36.60 Average PT from Brokerages

Shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSAGet Free Report) have earned an average rating of “Buy” from the six ratings firms that are covering the stock, MarketBeat.com reports. Six equities research analysts have rated the stock with a buy rating. The average 1 year price target among brokerages that have issued a report on the stock in the last year is $37.17.

Several equities analysts have weighed in on KNSA shares. Citigroup started coverage on Kiniksa Pharmaceuticals in a report on Thursday. They issued a “buy” rating and a $40.00 price objective for the company. Wedbush reaffirmed an “outperform” rating and issued a $34.00 price objective on shares of Kiniksa Pharmaceuticals in a report on Tuesday, February 25th.

Check Out Our Latest Stock Report on KNSA

Kiniksa Pharmaceuticals Stock Performance

Shares of KNSA stock opened at $22.61 on Thursday. The firm’s 50 day moving average price is $19.99 and its two-hundred day moving average price is $22.16. Kiniksa Pharmaceuticals has a 52-week low of $16.56 and a 52-week high of $28.15. The stock has a market cap of $1.64 billion, a PE ratio of -161.49 and a beta of 0.48.

Kiniksa Pharmaceuticals (NASDAQ:KNSAGet Free Report) last posted its quarterly earnings data on Tuesday, February 25th. The company reported ($0.12) earnings per share for the quarter, missing the consensus estimate of ($0.06) by ($0.06). The firm had revenue of $122.50 million for the quarter, compared to the consensus estimate of $123.42 million. Kiniksa Pharmaceuticals had a negative return on equity of 7.31% and a negative net margin of 2.36%. The firm’s quarterly revenue was up 46.9% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.35 EPS. As a group, sell-side analysts predict that Kiniksa Pharmaceuticals will post -0.55 earnings per share for the current fiscal year.

Insider Activity at Kiniksa Pharmaceuticals

In other news, CAO Michael R. Megna sold 9,051 shares of the firm’s stock in a transaction that occurred on Wednesday, March 12th. The shares were sold at an average price of $22.45, for a total value of $203,194.95. Following the sale, the chief accounting officer now directly owns 26,528 shares in the company, valued at approximately $595,553.60. This trade represents a 25.44 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CFO Mark Ragosa sold 36,372 shares of the firm’s stock in a transaction that occurred on Wednesday, March 12th. The shares were sold at an average price of $22.25, for a total transaction of $809,277.00. Following the completion of the sale, the chief financial officer now owns 22,958 shares in the company, valued at approximately $510,815.50. The trade was a 61.30 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 73,423 shares of company stock valued at $1,541,812 over the last ninety days. 54.57% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Kiniksa Pharmaceuticals

A number of hedge funds have recently made changes to their positions in KNSA. Quarry LP bought a new stake in shares of Kiniksa Pharmaceuticals during the third quarter worth about $50,000. Lazard Asset Management LLC acquired a new stake in shares of Kiniksa Pharmaceuticals in the fourth quarter valued at about $61,000. Zurcher Kantonalbank Zurich Cantonalbank acquired a new stake in shares of Kiniksa Pharmaceuticals in the third quarter valued at about $189,000. KLP Kapitalforvaltning AS acquired a new stake in shares of Kiniksa Pharmaceuticals in the fourth quarter valued at about $158,000. Finally, Bellevue Group AG acquired a new stake in shares of Kiniksa Pharmaceuticals in the fourth quarter valued at about $160,000. 53.95% of the stock is currently owned by institutional investors and hedge funds.

About Kiniksa Pharmaceuticals

(Get Free Report

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.

Read More

Analyst Recommendations for Kiniksa Pharmaceuticals (NASDAQ:KNSA)

Receive News & Ratings for Kiniksa Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kiniksa Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.